CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Organon & Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Organon & Co
30 Hudson Street, Fl 33
Phone: (551) 430-6000p:551 430-6000 JERSEY CITY, NJ  07302  United States Ticker: OGNOGN

Business Summary
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Carrie S.Cox 65 1/1/2021 1/1/2021
Chief Executive Officer, Director KevinAli 63 1/1/2021 1/1/2021
Chief Financial Officer, Executive Vice President Matthew M.Walsh 56
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Forendo Pharma Oy Itinen Pitkkatu 4 B Turku Finland

Business Names
Business Name
Alydia Health
Alydia Health, Inc.
AND SCIENTIFIC OFFICES
120 additional Business Names available in full report.

General Information
Number of Employees: 10,000 (As of 12/31/2023)
Outstanding Shares: 255,638,256 (As of 2/20/2024)
Shareholders: 69,973
Stock Exchange: NYSE
Federal Tax Id: 852269702
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024